''....Reslizumab is current approved for intravenous injection, and Teva had hoped to win an expanded indication for subcutaneous dosing using prefilled syringes. Both of the new trials missed their primary endpoints: significantly reducing exacerbations in the first, among patients with uncontrolled asthma, and reducing oral corticosteroid doses in the second, which enrolled patients dependent on oral steroids to maintain control.....''
1. The term 'approval' used above, may refer to the USA, as the Quotation Source is, I think, American
2. Won't be able to answer any questions on this as I have little knowledge of Reslizumab (the Biological / Mab, in question).
Thanks in advance for any Comments / Thoughts - and apologies if I don't have time to make a personal response.